Sales rose 10% to RON22.92 million, from RON20.82 million in January-June2010, according to the company’s financial report.
Revenue fell 15.4% on the year in the interval analyzed, to RON19.82 million, while overall expenditure dropped 8.6% to RON18.67 million.
The company expects turnover to rise by an annual 10%-25% in 2012-2013, frRON47.5 million last year.
The Buzoianu brothers unfolded a takeover offer on May 6-26, for the 41.84% in the company they did not own. Following the operation, the two brothers now hold 80.2% in the company.
Retrasib has a share capital of RON5 million, divided into 50 million shares, with a face value of RON0.1.
Mid-session Thursday, Retrasib shares were trading at RON0.528, up 1.44% on the day. (EUR1=RON4.2445)